Are You a Good Candidate for Stem Cell Joint Therapy?

If joint pain has become part of your daily routine, you have probably searched for alternatives to long-term pain medication or joint replacement surgery. Regenerative options like stem cell joint therapy get a lot of attention online, but not everyone with achy knees, hips, or shoulders is an ideal candidate. Candidacy depends on the severity of your arthritis, your symptom pattern, your overall health, and what you have already tried. This guide walks through the factors a physician actually weighs before recommending stem cell joint regeneration, so you can have a more informed conversation at your evaluation.

What stem cell joint therapy actually involves

At Utah Stem Cells, joint injections use cells derived from donated umbilical cord and amniotic tissue, processed in a lab under strict screening protocols. These are not cells taken from your own bone marrow or fat. The donated tissue is chosen because it is rich in the growth factors and signaling molecules thought to support a calmer, more favorable environment inside an arthritic joint. This is different from platelet-rich plasma (PRP), which is prepared from your own blood and is also autologous by definition. Some patients use PRP and donor-derived cellular therapy together, or move from one to the other, depending on how their joint pain responds. Our article comparing PRP vs. stem cells for joint pain breaks down how the two approaches differ mechanically.

Neither option is a surgical implant or a drug in the traditional sense, and neither is FDA-approved as a cure for arthritis. We cover what that regulatory status actually means for patients in our post on whether stem cell therapy is FDA-approved.

How severity of arthritis affects candidacy

The single biggest factor in candidacy is how advanced your joint degeneration is, typically measured on the Kellgren-Lawrence (KL) scale, a standard radiographic grading system that runs from 0 (no arthritis) to 4 (severe, bone-on-bone).

Published research on mesenchymal stem cell injections for knee osteoarthritis consistently points to the same pattern: patients with early to moderate disease, generally KL grades I through III, tend to report more meaningful improvement in pain and function than those with grade IV disease. A recent propensity-matched cohort study found that patients with KL grade 2–3 osteoarthritis had greater functional and quality-of-life gains after stem cell injection than those with grade 4 changes, and some clinical trials exclude grade 4 disease in patients over 60 outright. A 2023 systematic review pooling data from 539 patients across 12 studies reported that regenerative injections were a “safe, reliable, and effective” option specifically for KL grade I–III knees, with pain scores improving by roughly 1 to 5 points on standard scales over follow-up periods of three months to five years.

That does not mean grade IV, bone-on-bone arthritis rules you out for every regenerative option. It does mean expectations need to be realistic, and a physician may recommend a different treatment path, or a combination approach, once the joint has advanced that far. Our review of stem cell research on knee osteoarthritis goes deeper into how outcomes are measured in these studies.

Who tends to be a good candidate

Based on the clinical literature and our own evaluation criteria, good candidates for stem cell joint therapy generally share several traits:

• Early to moderate arthritis (roughly KL grade I–III) confirmed by imaging, rather than end-stage, bone-on-bone joint collapse.
• Joint-specific pain that is limiting activity but has not progressed to constant, severe pain at rest.
• Reasonable cartilage space remaining on X-ray or MRI, giving the joint structure something to respond to.
• Realistic goals, such as reducing pain, improving function, and delaying more invasive procedures, rather than expecting a permanent cure.
• A history of conservative treatment, including physical therapy, activity modification, or anti-inflammatory approaches, that has not fully resolved symptoms.
• General health status that supports a low-risk outpatient injection, without active infection, uncontrolled autoimmune disease, or certain cancers in the treated area.

Patients dealing with hip or shoulder pain follow similar logic. If you have been told your shoulder pain won’t go away despite rest and physical therapy, or you are weighing options for a hip that has developed arthritis, the same severity and health-history questions apply.

Who is usually not a good fit

A physician may steer you away from stem cell joint therapy, or toward a different plan first, if you have:

• Severe, bone-on-bone arthritis with significant joint deformity
• An active infection, either in the joint or systemically
• Uncontrolled autoimmune or inflammatory disease
• A recent or active cancer diagnosis, in some cases
• Symptoms that point to a mechanical problem, like a large meniscal tear or ligament instability, that likely needs surgical repair rather than a biologic injection

None of this is a judgment you should make on your own. It is exactly the kind of decision that benefits from imaging review and a hands-on exam.

How this compares with other options

Most patients considering stem cell joint therapy are also weighing cortisone shots, PRP, or eventual joint replacement. Each has a different risk and benefit profile:

• Cortisone injections can reduce inflammation quickly but are typically limited to a few uses per year because repeated injections may weaken cartilage over time. Our comparison of stem cells vs. cortisone for knee arthritis looks at how the research stacks up.
• PRP uses your own blood-derived platelets and growth factors and is often used as a first step or alongside donor-derived cellular therapy.
• Joint replacement surgery remains the most predictable option for severe, end-stage arthritis, but it is a major procedure with a lengthy recovery, which is why many patients look for ways to delay it as long as it is medically reasonable. Our article on whether you can avoid knee replacement with stem cell therapy discusses this trade-off honestly.

None of these options guarantees a specific outcome, and results vary from person to person based on the severity of joint damage, overall health, and how the body responds.

What to expect at your evaluation

A candidacy evaluation at Utah Stem Cells starts with a review of your symptoms, activity limitations, and prior treatments, followed by a physical exam and a look at recent imaging when available. Dr. William Cimikoski and the clinical team will walk through whether your KL grade and overall health profile make you a reasonable candidate, what realistic outcomes look like for someone in your situation, and how stem cell therapy might fit alongside PRP or other conservative measures. If you are earlier in your research, our guide on how to choose a stem cell clinic outlines the questions worth asking any provider, including ours.

Frequently asked questions

What KL grade is best for stem cell joint therapy?

Research generally shows the most favorable outcomes in KL grades I through III (mild to moderate osteoarthritis). Grade IV, or bone-on-bone arthritis, tends to respond less predictably, though a physician can still discuss options after evaluating your specific joint.

Does Utah Stem Cells use my own stem cells?

No. The cellular therapy used for joint injections comes from donated umbilical cord and amniotic tissue that is screened and processed in a lab, not cells harvested from your own bone marrow or fat. PRP, when used, is prepared from your own blood.

How many injections will I need?

This varies by joint, severity, and how you respond, and is determined individually. Some patients receive a single injection, while others discuss a series or a combination with PRP during their evaluation.

Is stem cell joint therapy FDA-approved?

No regenerative injection for arthritis currently carries FDA approval as a cure for osteoarthritis. It is important to understand this regulatory landscape before starting treatment; see our full explanation of FDA approval status.

Will insurance cover this treatment?

Coverage varies by plan and is best confirmed directly with your insurer and our office during scheduling, since coverage policies for regenerative injections differ widely.

What if I am not a good candidate?

If imaging or your exam suggests you are not a strong candidate, we will discuss alternatives, which may include PRP, activity and lifestyle changes, referral for further imaging, or a conversation about surgical options with an orthopedic specialist.

This article is for general education. It is not medical advice or a promise of any particular result. Stem cell therapy is not an FDA-approved cure for arthritis, individual outcomes vary, and candidacy can only be determined by a physician after an individual evaluation. Book a consultation with Utah Stem Cells to discuss whether stem cell joint therapy may be appropriate for you.